tbuckley/cabot-search huggingface dataset:
Preclinical Characterization of Pharmacologic <scp>NAD</scp><sup>+</sup> Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis
Authors: Carlos Perez‐Sanchez, Alejandro Escudero‐Contreras, Tomás Cerdó, Luz Marina Sánchez‐Mendoza, Adrián Llamas‐Urbano, Iván Arias‐de la Rosa, Miguel Pérez‐Rodriguez, Laura Muñoz‐Barrera, María del Carmen Abalos‐Aguilera, Nuria Barbarroja, Jerusalem Calvo, Rafaela Ortega‐Castro, Desiree Ruiz‐Vilchez, Juan Antonio Moreno, María Isabel Burón, José Antonio González‐Reyes, Eduardo Collantes‐Estevez, Chary Lopez‐Pedrera, José Manuel Villalba
Journal: Arthritis & Rheumatology (2023)

We analyzed NAD+ metabolism in patients with rheumatoid arthritis (RA), its association with disease activity and clinical outcomes of RA, and the therapeutic potential of pharmacologic NAD+ boosting.Our study included 253 participants. In the first cohort, comprising 153 RA patients and 56 healthy donors, we assessed NAD+ levels and NAD+ -related gene pathways. We analyzed 92 inflammatory molecules by proximity extension assay. In the second cohort, comprising 44 RA patients starting anti-tumor necrosis factor (anti-TNF) drugs, we evaluated changes in NAD+ levels and their association with clinical response after 3 months. Mechanistic studies were performed ex vivo on peripheral blood mononuclear cells (PBMCs) from patients with RA to test the beneficial effects of NAD+ boosters, such as nicotinamide and nicotinamide riboside.Reduced NAD+ levels were found in RA samples, in line with altered activity and expression of genes involved in NAD+ consumption (sirtuins, poly[ADP-ribose] polymerase, CD38), transport (connexin 43), and biosynthesis (NAMPT, NMNATs). Unsupervised clustering analysis identified a group of RA patients with the highest inflammatory profile, the lowest NAD+ levels, and the highest disease activity (as shown by the Disease Activity Score in 28 joints). NAD+ levels were modulated by anti-TNF therapy in parallel with the clinical response. In vitro studies using PBMCs from RA patients showed that nicotinamide riboside and nicotinamide increased NAD+ levels via NAMPT and NMNAT and reduced their prooxidative, proapoptotic, and proinflammatory status.RA patients display altered NAD+ metabolism, directly linked to their inflammatory and disease activity status, which was reverted by anti-TNF therapy. The preclinical beneficial effects of NAD+ boosters, as shown in leukocytes from RA patients, along with their proven clinical safety, might pave the way for the development of clinical trials using these compounds.
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
Authors: Liangtao Ye, Julia S Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N De Toni, Changhua Zhang, Florian P Reiter
Journal: Liver Cancer (2023)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic differentiation. &lt;b&gt;&lt;i&gt;Summary:&lt;/i&gt;&lt;/b&gt; Because of its aggressive nature, patients with cHCC-iCCA exhibit a poorer prognosis than those with HCC. Surgical resection and liver transplantation may be considered curative treatment approaches; however, only a minority of patients are eligible at the time of diagnosis, and postoperative recurrence rates are high. For cases that are not eligible for surgery, locoregional and systemic therapy are often administered based on treatment protocols applied for HCC or iCCA. Owing to the rarity of this cancer, there are still no established standard treatment protocols; therefore, the choice of therapy is often personalized and guided by the suspected predominant component. Further, the genomic and molecular heterogeneity of cHCC-iCCA can severely compromise the efficacy of the available therapies. &lt;b&gt;&lt;i&gt;Key Messages:&lt;/i&gt;&lt;/b&gt; In the present review, we summarize the latest advances in cHCC-iCCA and attempt to clarify its terminology and molecular biology. We provide an overview of the etiology of cHCC-iCCA and present new insights into the molecular pathology of this disease that could contribute to further studies aiming to improve the patient outcomes through new systemic therapies.
Annals Story Slam - Loss of a Best Friend
Authors: Ivan Marbley
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMay 2023Annals Story Slam - Loss of a Best FriendFREEIvan MarbleyIvan MarbleySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W23-0009 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Loss of a Best Friend "Loss of a Best Friend," by Ivan Marbley. (Duration 9:21)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam.This story was shared at the “Gun Injury: Stories of Hurt, Hope, and Resilience” Story Slam event, held at WHYY in Philadelphia on 7 December 2022. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Ivan MarbleyThis article was published at Annals.org on 25 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMay 2023Volume 176, Issue 5 ePublished: 25 April 2023 Issue Published: May 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Annals Story Slam - Treating a Gunshot Victim
Authors: Sanjay Nadesan
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMay 2023Annals Story Slam - Treating a Gunshot VictimFREESanjay Nadesan, MDSanjay Nadesan, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W23-0002 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Treating a Gunshot Victim "Treating a Gunshot Victim," by Sanjay Nadesan, MD. (Duration 3:55)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam.This story was shared at the “Gun Injury: Stories of Hurt, Hope, and Resilience” Story Slam event, held at WHYY in Philadelphia on 7 December 2022. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Sanjay Nadesan, MDThis article was published at Annals.org on 25 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMay 2023Volume 176, Issue 5 ePublished: 25 April 2023 Issue Published: May 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Annals Story Slam - The Dichotomy
Authors: Hannah Troutman
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMay 2023Annals Story Slam - The DichotomyFREEHannah Troutman, DOHannah Troutman, DOSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W23-0007 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The Dichotomy "The Dichotomy," by Hannah Troutman, DO. (Duration 2:47)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam.This story was shared at the “Gun Injury: Stories of Hurt, Hope, and Resilience” Story Slam event, held at WHYY in Philadelphia on 7 December 2022. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Hannah Troutman, DOThis article was published at Annals.org on 25 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics May 2023Volume 176, Issue 5 ePublished: 25 April 2023 Issue Published: May 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Annals Story Slam - Overcoming Anger Through Running
Authors: Jermaine Millhouse
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMay 2023Annals Story Slam - Overcoming Anger Through RunningFREEJermaine MillhouseJermaine MillhouseSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W23-0006 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Overcoming Anger Through Running "Overcoming Anger Through Running," by Jermaine Millhouse. (Duration 7:22)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam.This story was shared at the “Gun Injury: Stories of Hurt, Hope, and Resilience” Story Slam event, held at WHYY in Philadelphia on 7 December 2022. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Jermaine MillhouseThis article was published at Annals.org on 25 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics May 2023Volume 176, Issue 5 ePublished: 25 April 2023 Issue Published: May 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Effects of Cognitive Behavioral Therapy and Cash Transfers on Older Persons Living Alone in India
Authors: Madeline McKelway, Abhijit Banerjee, Erin Grela, Frank Schilbach, Miriam Sequeira, Garima Sharma, Girija Vaidyanathan, Esther Duflo
Journal: Annals of Internal Medicine (2023)

A growing number of older persons in developing countries live entirely alone and are physically, mentally, and financially vulnerable.To determine whether phone-based cognitive behavioral therapy (CBT) or a cash transfer reduce functional impairment, depression, or food insecurity in this population.Randomized controlled trial. (ClinicalTrials.gov: NCT04225845; American Economic Association RCT Registry: AEARCTR-0007582).Tamil Nadu, India, 2021.1120 people aged 55 years and older and living alone.A 6-week, phone-based CBT and a 1-time cash transfer of 1000 rupees (U.S. $12 at market exchange rates) were evaluated in a factorial design.The World Health Organization Disability Assessment Schedule (WHODAS), the Geriatric Depression Scale, and food security, all measured 3 weeks after CBT for 977 people and 3 months after for 932. Surveyors were blind to treatment assignment.The WHODAS score (scale 0 to 48, greater values representing more impairment) decreased between baseline and the 3-week follow-up by 2.92 more (95% CI, -5.60 to -0.23) in the group assigned cash only than in the control group, and the depression score (ranging from 0 to 15, higher score indicating more depressive symptoms) decreased by 1.01 more (CI, -2.07 to 0.06). These effects did not persist to the 3-month follow-up, and CBT alone and the 2 together had no significant effects. There were no effects on food security.The study cannot say whether more sustained or in-person therapy would have been effective, how results would translate outside of the COVID-19 period, or whether results in the consented sample differ from those in a larger population. Primary outcomes were self-reported.Among older people living alone, a small cash transfer was effective in alleviating short-term (3 weeks) functional impairment, produced a small but not clinically or statistically significant reduction in depression, and had no effect on food security. There were no short-term effects from CBT or the 2 interventions together. None of the interventions showed any effect at 3 months.National Institute on Aging (NIA).
Infectious Diseases: What You May Have Missed in 2022
Authors: Rand Al Ohaly, Marie-Eve Benoit, Mindy G. Schuster
Journal: Annals of Internal Medicine (2023)

In 2022, COVID-19 remained the infectious disease at the top of most internal medicine physicians' minds. However, it was not the only infectious disease that was the topic of clinically relevant research that year. This article highlights some important infectious disease evidence unrelated to COVID-19 that was published in 2022. The literature was screened for sound new evidence relevant to internal medicine specialists and subspecialists whose focus of practice is not infectious diseases. The publications highlighted relate to various organisms in different patient populations. One article provides insight into the role of Helicobacter pylori eradication in the treatment of functional dyspepsia. The descriptive epidemiology of bacterial (Staphylococcus aureus) and viral (mpox) infections are the focus of 2 other articles. Several articles address the management of resistant and difficult-to-treat infections: multidrug-resistant gram-negative infections, resistant HIV-1, rifampin-resistant tuberculosis, cryptococcal meningitis, and invasive fungal infection in the setting of neutropenia. Another article provides data on effective HIV preexposure prophylaxis in women, an understudied population. Finally, given the urgent need to reduce inappropriate use of antibiotics, an article on antibiotic stewardship for hospitalized patients with presumed sepsis in a non-intensive care unit setting is also included.
The Natural Sequence in Which Subclinical Inflamed Joint Tissues Subside or Progress to Rheumatoid Arthritis: A Study of Serial <scp>MRIs</scp> in the <scp>TREAT EARLIER</scp> Trial
Authors: Doortje I. Krijbolder, Xanthe M. E. Matthijssen, Bastiaan T. van Dijk, Hanna W. van Steenbergen, Debbie M. Boeters, Annemiek Willemze, Anne A. Schouffoer, Annette H. M. van der Helm‐van Mil
Journal: Arthritis & Rheumatology (2023)

The natural trajectory of clinical arthritis progression at the tissue level remains elusive. We hypothesized that subclinical inflammation in different joint tissues (synovitis, tenosynovitis, osteitis) increases in a distinct temporal order in patients with clinically suspect arthralgia (CSA) who develop rheumatoid arthritis (RA) and subsides in a different sequence when CSA spontaneously resolves.
Annals Graphic Medicine - Dr. Mom: Stethoscope Stories
Authors: Grace E. Farris
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMay 2023Annals Graphic Medicine - Dr. Mom: Stethoscope StoriesFREEGrace E. Farris, MDGrace E. Farris, MDUniversity of Texas, Austin, Texas (G.E.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G23-0015 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Grace E. Farris, MDAffiliations: University of Texas, Austin, Texas (G.E.F.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G22-0020.Author/Illustrator Information: Grace E. Farris, MD, is an assistant professor of medicine at Dell Medical School at the University of Texas in Austin, Texas. You can view her work at her website: www.farrisgrace.com.About Dr. Mom: In Dr. Mom, physician and cartoonist Grace Farris examines work–life balance while mothering and doctoring. Dr. Mom appears quarterly in Annals Graphic Medicine at Annals.org.This article was published at Annals.org on 25 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMay 2023Volume 176, Issue 5 ePublished: 25 April 2023 Issue Published: May 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Annals Story Slam - A Patient Named Ted
Authors: Amy Davis
Journal: Annals of Internal Medicine (2023)

Web ExclusivesMay 2023Annals Story Slam - A Patient Named TedFREEAmy Davis, DOAmy Davis, DOSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W23-0001 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - A Patient Named Ted "A Patient Named Ted," by Amy Davis, DO. (Duration 5:08)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam.This story was shared at the “Gun Injury: Stories of Hurt, Hope, and Resilience” Story Slam event, held at WHYY in Philadelphia on 7 December 2022. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Amy Davis, DOThis article was published at Annals.org on 25 April 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Current IssueMay 2023Volume 176, Issue 5 ePublished: 25 April 2023 Issue Published: May 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.Loading ...
Trends in the Prevalence of Stroke Among Community-Dwelling Individuals in the US, 1999-2018
Authors: Wells Andres, Aaron Rothstein, Holly Elser, Kelly L. Sloane, Rebecca F. Gottesman, Scott E. Kasner, Andrea L. C. Schneider
Journal: JAMA Neurology (2023)

This cross-sectional study estimates trends in stroke prevalence representative of the noninstitutionalized civilian population of US adults 20 years and older using data from the 1999 to 2018 National Health and Nutrition Examination Surveys.
Phase-Contrast Magnetic Resonance Imaging of Inhaled Xenon Reveals the Relationship between Airflow and Obstruction in Obstructive Sleep Apnea
Authors: Qiwei Xiao, Neil Stewart, Matthew Willmering, Keith McConnell, Jason Woods, Robert Fleck, Raouf Amin, Alister Bates
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Phase-Contrast Magnetic Resonance Imaging of Inhaled Xenon Reveals the Relationship between Airflow and Obstruction in Obstructive Sleep Apnea." American Journal of Respiratory and Critical Care Medicine, 208(3), pp. e5–e6
Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis
Authors: Bernd W M Arents
Journal: British Journal of Dermatology (2023)

Journal Article Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis Get access Bernd W M Arents Bernd W M Arents Writing - original draft Dutch Association for People with Atopic Dermatitis, Nijkerk, the Netherlands Correspondence: Bernd W.M. Arents. Email: bernd@vmce.nl https://orcid.org/0000-0001-6884-8014 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 188, Issue 6, June 2023, Page 694, https://doi.org/10.1093/bjd/ljad068 Published: 24 April 2023 Article history Received: 28 February 2023 Accepted: 17 March 2023 Corrected and typeset: 24 April 2023 Published: 24 April 2023
Correction to: Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association
Journal: Circulation (2023)

corrections were needed.1.In the supplemental material, in eTable 4, on page 7, fifth row ("dabigatran"), fifth column ("Clinical Monitoring and Dose Adjustment"), the third entry read, "Reduce dose to 75 mg Twice Daily if coadministered with the dronedarone or ketoconazole." It has been updated to read, "Reduce dose to 75 mg Twice Daily if coadministered with dronedarone or systemic ketoconazole in patients with CrCl 30-50 mL/min." 2. In the supplemental material, in eTable 4, on page 8, second row ("apixaban"), fifth column ("Clinical Monitoring and Dose Adjustment"), the first entry read, "Reduce dose to 2.5 mg Twice Daily if Cr ≥1.5 mg/dL AND either ≥80 years of age or body weight ≤60 kg." It has been updated to read, "Reduce dose to 2.5 mg Twice Daily if any 2 of the following 3 criteria met: Cr ≥1.5 mg/dL, ≥80 years of age, body weight ≤60 kg.
Highlights From the <i>Circulation</i> Family of Journals
Authors: Mattias Duytschaever, Tom De Potter, Massimo Grimaldi, Ante Anic, Johan Vijgen, Petr Neuzil, Hugo Van Herendael, Atul Verma, Allan Skanes, Daniel Scherr, Helmut Pürerfellner, Gediminas Rackauskas, Pierre Jais, Vivek Reddy, Pieter Martens, Sanjeeb Bhattacharya, Joshua Longinow, Lauren Ives, Miriam Jacob, Jason Valent, Mazen Hanna, ; Wilson Tang, W Wilson Tang, Nadia Islam, Laura Wyatt, Shahmir Ali, Jennifer Zanowiak, Sadia Mohaimin, Keith Goldfeld, Priscilla Lopez, Rashi Kumar, Susan Beane, Lorna Thorpe, Chau Trinh-Shevrin, Haruhito Yuki, Tomoyo Sugiyama, Keishi Suzuki, Daisuke Kinoshita, Takayuki Niida, Akihiro Nakajima, Makoto Araki, Damini Dey, Hang Lee, Iris Mcnulty, Sunao Nakamura, Tsunekazu Kakuta, Ik-Kyung Jang
Journal: Circulation (2023)

The March highlights from the Circulation family of journals span a range of cardiovascular topics.The 1-year results of a novel variable-loop biphasic pulsed field ablation catheter on paroxysmal atrial fibrillation are described in Circulation: Arrhythmia and Electrophysiology.The hemodynamic profiles of amyloid cardiomyopathies are reported in Circulation: Heart Failure.A randomized trial shows the potential impact of community health workers on hypertension control in Circulation: Cardiovascular Quality and Outcomes.The association of pericoronary adipose tissue with features of plaque vulnerability is reported in Circulation: Cardiovascular Imaging.Last, the association of coronary flow reserve among patients with coronary microvascular dysfunction with events is described in Circulation: Cardiovascular Interventions.